Safety and Efficacy of Evolocumab in Ischemic Stroke
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT05697185
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Sponsor
- Second Affiliated Hospital of Guangxi Medical University
- Registry
-
NCT05697185
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT05697185. Randomized; single masking; primary purpose treatment. Start 2023-02-01 (anticipated); primary completion 2024-02-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Evolocumab in Ischemic Stroke
- Acronym
- SEEIS
- Condition
- Ischemic Stroke, Acute
- Intervention (Drug)
- Evolocumab
- Lead sponsor
- Second Affiliated Hospital of Guangxi Medical University
Record details
- Record id
cardio:ct-nct05697185- Content hash
129ef45c1543eb0f79aa4515e177234689f293d5360bb34796d4e01873c2ab3b